Nautilus Biotechnology, Inc. Payments to Acquire Debt Securities, Available-for-sale
Nautilus Biotechnology, Inc. (NAUT) reported Payments to Acquire Debt Securities, Available-for-sale of $28.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-28
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $17.43M, a 298.22% increase year-over-year.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $11.06M, a 60.32% increase year-over-year.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $33.72M, a 25.44% increase year-over-year.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $27.49M, a 37.09% decline year-over-year.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $72.49M, a 15.98% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $86.28M, a 23.57% decline from fiscal 2023.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $112.89M, a 39.50% decline from fiscal 2022.
- Nautilus Biotechnology, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $186.59M, a 15.87% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $28.50M 10-Q · filed 2026-07-28 | $62.22M derived: sum of 3 quarters · filed 2026-07-28 | $89.71M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $11.06M 10-Q · filed 2026-04-28 | $44.78M derived: sum of 2 quarters · filed 2026-04-28 | $72.27M derived: sum of 3 quarters · filed 2026-04-28 | $76.65M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $33.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $61.21M derived: sum of 2 quarters · filed 2026-02-26 | $65.59M derived: sum of 3 quarters · filed 2026-07-28 | $72.49M 10-K · filed 2026-02-26 |
| 2025-09-30 | $27.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $31.87M derived: sum of 2 quarters · filed 2026-07-28 | $38.77M 10-Q · filed 2025-10-28 | $65.65M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $4.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $11.28M 10-Q · filed 2026-07-28 | $38.16M derived: sum of 3 quarters · filed 2026-07-28 | $81.86M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $6.90M 10-Q · filed 2026-04-28 | $33.78M derived: sum of 2 quarters · filed 2026-04-28 | $77.48M derived: sum of 3 quarters · filed 2026-04-28 | $93.18M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $26.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $70.58M derived: sum of 2 quarters · filed 2026-02-26 | $86.28M derived: sum of 3 quarters · filed 2026-02-26 | $86.28M 10-K · filed 2026-02-26 |
| 2024-09-30 | $43.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $59.40M derived: sum of 2 quarters · filed 2025-10-28 | $59.40M 10-Q · filed 2025-10-28 | $120.39M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | $15.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $15.69M 10-Q · filed 2025-07-31 | $76.69M derived: sum of 3 quarters · filed 2025-07-31 | $81.74M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-29 | $61.00M derived: sum of 2 quarters · filed 2025-04-29 | $66.05M derived: sum of 3 quarters · filed 2025-04-29 | $85.84M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $66.05M derived: sum of 2 quarters · filed 2025-02-27 | $85.84M derived: sum of 3 quarters · filed 2025-02-27 | $112.89M 10-K · filed 2025-02-27 |
| 2023-09-30 | $5.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $24.84M derived: sum of 2 quarters · filed 2024-10-29 | $51.90M 10-Q · filed 2024-10-29 | $136.82M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $19.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $46.84M 10-Q · filed 2024-07-30 | $131.77M derived: sum of 3 quarters · filed 2024-07-30 | $179.25M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $27.05M 10-Q · filed 2024-04-30 | $111.98M derived: sum of 2 quarters · filed 2024-04-30 | $159.46M derived: sum of 3 quarters · filed 2024-04-30 | $190.73M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | $84.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $132.41M derived: sum of 2 quarters · filed 2024-02-28 | $163.68M derived: sum of 3 quarters · filed 2024-02-28 | $186.59M 10-K · filed 2024-02-28 |
| 2022-09-30 | $47.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $78.75M derived: sum of 2 quarters · filed 2023-10-31 | $101.67M 10-Q · filed 2023-10-31 | $139.72M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | $31.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $54.19M 10-Q · filed 2023-08-02 | $92.23M derived: sum of 3 quarters · filed 2023-08-02 | $175.94M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $22.91M 10-Q · filed 2023-05-02 | $60.96M derived: sum of 2 quarters · filed 2023-05-02 | $144.67M derived: sum of 3 quarters · filed 2023-05-02 | $244.71M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $38.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $121.76M derived: sum of 2 quarters · filed 2023-02-23 | $221.79M derived: sum of 3 quarters · filed 2023-02-23 | $221.79M 10-K · filed 2023-02-23 |
| 2021-09-30 | $83.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $183.75M derived: sum of 2 quarters · filed 2022-11-01 | $183.75M 10-Q · filed 2022-11-01 | $183.75M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $100.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $100.03M 10-Q · filed 2022-08-02 | $100.03M derived: sum of 3 quarters · filed 2022-08-02 | $120.06M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-03 | $0.00 derived: sum of 2 quarters · filed 2022-05-03 | $20.03M derived: sum of 3 quarters · filed 2022-05-03 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $20.03M derived: sum of 2 quarters · filed 2022-02-24 | $68.36M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $20.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $68.36M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $48.33M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |